Patents by Inventor Inger Sandlie
Inger Sandlie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160033523Abstract: The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for HSA binding to the FcRn receptor in said animal. In the non-primate animal species, the binding affinity of wild type HSA to the native FcRn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native FcRn. The present invention also relate to animal models which are particularly suitable for assessing pharmacokinetics of human serum albumin variants.Type: ApplicationFiled: February 14, 2014Publication date: February 4, 2016Inventors: Jason Cameron, Darrell Sleep, Jan Terje Andersen, Inger Sandlie
-
Publication number: 20160009787Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: September 24, 2015Publication date: January 14, 2016Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Patent number: 9169322Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: January 19, 2012Date of Patent: October 27, 2015Assignee: Vaccibody ASInventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
-
Patent number: 9056920Abstract: The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II ? chain; (ii) all or part of the extracellular portion of an MHC class II ? chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the ?2 domain of said ? chain and the ?2 domain of said ? chain, wherein said cysteine residues are not present in native MHC class II ?2 and ?2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects.Type: GrantFiled: July 14, 2014Date of Patent: June 16, 2015Assignee: Universitetet I OsloInventors: Geir Age Loset, Terje Frigstad, Inger Sandlie, Bjarne Bogen
-
Patent number: 8932603Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: February 25, 2004Date of Patent: January 13, 2015Assignee: Vaccibody ASInventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
-
Publication number: 20140349315Abstract: The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II ? chain; (ii) all or part of the extracellular portion of an MHC class II ? chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the ?2 domain of said ? chain and the ?2 domain of said ? chain, wherein said cysteine residues are not present in native MHC class II ?2 and ?2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects.Type: ApplicationFiled: July 14, 2014Publication date: November 27, 2014Applicant: Universitetet I OsloInventors: Geir Age Loset, Terje Frigstad, Inger Sandlie, Bjarne Bogen
-
Publication number: 20140315816Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Patent number: 8828379Abstract: The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II ? chain; (ii) all or part of the extracellular portion of an MHC class II ? chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the ?2 domain of said ? chain and the ?2 domain of said ? chain, wherein said cysteine residues are not present in native MHC class II ?2 and ?2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects.Type: GrantFiled: February 18, 2011Date of Patent: September 9, 2014Assignee: Universitetet I OsloInventors: Geir Age Loset, Terje Frigstad, Inger Sandlie, Bjarne Bogen
-
Patent number: 8822417Abstract: Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.Type: GrantFiled: May 4, 2012Date of Patent: September 2, 2014Assignee: Novozymes Biopharma DIC A/SInventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Publication number: 20140234311Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Patent number: 8748380Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: GrantFiled: November 1, 2010Date of Patent: June 10, 2014Assignee: Novozymes Biopharma DK A/SInventors: Andrew Plumridge, Darrell Sleep, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20130225496Abstract: The invention relates to variants of albumin. The invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of preparing the variants and to methods of using the variants.Type: ApplicationFiled: November 1, 2011Publication date: August 29, 2013Applicant: Novozymes Biopharma DK A/SInventors: Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20130028930Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.Type: ApplicationFiled: April 8, 2011Publication date: January 31, 2013Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis
-
Publication number: 20120322739Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: May 4, 2012Publication date: December 20, 2012Applicants: Novozymes Biopharma UK Limited, Novozymes Biopharma DK A/S, Novozymes A/S, University of OsloInventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Publication number: 20120231525Abstract: The present invention relates to vectors, methods and systems for polypeptide display and selection. Specifically, the present invention relates to vectors, methods, and systems for multivalent phage display using pIX protein of filamentous phage and helper phage.Type: ApplicationFiled: September 21, 2010Publication date: September 13, 2012Applicant: University of OsloInventors: Geir Age Loset, Inger Sandlie
-
Publication number: 20120220530Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: November 1, 2010Publication date: August 30, 2012Applicant: Novozymes Biopharma DK A/SInventors: Andrew Plumridge, Darrell Sleep, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20120171242Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: January 19, 2012Publication date: July 5, 2012Applicant: VACCIBODY ASInventors: Bjarne BOGEN, Agnete Brunsvik Fredriksen, Inger SANDLIE
-
Publication number: 20040253238Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: February 25, 2004Publication date: December 16, 2004Inventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
-
Publication number: 20040175786Abstract: The invention relates to a single-chain antibody which is characterized in that (a) it contains a variable domain (scFv) binding specifically to human CD3, and (b) its constant domains are derived from a human IgM molecule and comprise the C&mgr;3 domain and the C&mgr;4 domain but not the C&mgr;1 domain and the C&mgr;2 domain. In a preferred embodiment, the antibody according to the invention contains a human IgG3 hinge region between the variable and constant domains. The invention also relates to DNA sequences coding for this antibody and to expression vectors containing these DNA sequences and finally to preparations containing the above compounds, preferably for the prevention of acute rejection reactions following organ transplantation.Type: ApplicationFiled: February 10, 2003Publication date: September 9, 2004Inventors: Ingrid Choi, Melvyn Little, Inger Sandlie
-
Patent number: 6294654Abstract: A modified immunoglobulin (Ig) molecule incorporates, preferably in one or more non-CDR loops, one or more foreign antigenic peptides such as a ras peptide. The antigen binding site of the immunoglobulin preferably recognises dendritic antigen presenting cells (APCs). The modified Ig can thus be taken up by dendritic APCs and the foreign antigenic peptide presented on MHC II to naive T-helper cells which stimulate cytotoxic T-cells via the production inter alia of IL-2. Modified Igs of the invention can be used to stimulate the immune system which has apparently become tolerant of a mutant protein, e.g., in the case of certain types of cancer, or it could be used for vaccination against viral infections. The modified Ig can be expressed from recombinant host cells from which it is secreted, notwithstanding the presence of the foreign pepide in a loop of the molecule.Type: GrantFiled: September 29, 1997Date of Patent: September 25, 2001Inventors: Bjarne Bogen, Inger Sandlie, Sigbjørn Fossum, Siri Mjaaland, Elin Lunde, Ingunn B. Rasmussen